Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. Senior Vice President, Devices reported equity compensation activity. On December 8, 2025, the executive acquired 38,078 restricted stock units (RSUs), each equal to one share of common stock awarded as compensation in lieu of cash, with 100% of the RSUs vesting on that date. To cover income tax withholding for the vested RSUs, 15,172 shares were withheld by BioCardia, which is not a sale by the executive. After these transactions, the executive beneficially owned 31,874 shares of common stock. The filing also reports a grant of a stock option for 20,000 shares at an exercise price of $1.37 per share, expiring on December 8, 2035, vesting as to 1/48th of the shares starting January 8, 2026 and monthly thereafter, contingent on continued service.
BioCardia, Inc. director reports new stock option grant
A BioCardia, Inc. director filed a Form 4 reporting the grant of a stock option on 12/08/2025. The option gives the right to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. According to the filing, all of these shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date.
After this grant, the reporting person beneficially owns 15,313 derivative securities, held directly. The option is shown with an expiration date of 12/08/2035, providing a long-term window during which the director may choose to exercise the option once vested.
BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.
BioCardia, Inc. director receives new stock option grant. A company director reported receiving a stock option to buy 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share, granted on 12/08/2025.
According to the filing, all of the shares under this option vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date. After this grant, the reporting person beneficially owns 15,573 derivative securities (stock options) on a direct basis, with the reported option expiring on 12/08/2035.
BioCardia, Inc. reported an insider equity award for one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option is classified as a derivative security because it represents the right to buy common stock in the future at a fixed price.
All 12,000 option shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues to serve as a service provider through that date. The option expires on 12/08/2035 if not exercised earlier. After this grant, the director beneficially owns 12,000 derivative securities directly in the form of this stock option.
BioCardia, Inc. filed an initial ownership report showing no securities held by the reporting director. A Form 3 was filed for an individual who serves as a director of BioCardia, Inc. (ticker BCDA) for an event dated 12/02/2025. The filing indicates that the form is filed by one reporting person and includes a remark stating that no securities are beneficially owned. An Exhibit 24 power of attorney is referenced, authorizing the signatory to sign on behalf of the reporting person.
BioCardia, Inc. (BCDA) reported an organizational update. The company announced in an 8-K that, on November 24, 2025, it issued a press release appointing Farhan Shahab as Vice President of Quality. This role typically oversees and supports quality systems and compliance for products and operations, which is important for companies operating in regulated medical and life science markets.
The press release describing the appointment is included as Exhibit 99.1, and the company notes that this information is being furnished, not filed, under securities laws, meaning it is provided for disclosure purposes without triggering certain liability provisions.
BioCardia, Inc. filed a current report to furnish its latest quarterly results update. On November 12, 2025, the company issued a press release announcing its financial results for the quarter ended September 30, 2025, and attached that release as an exhibit.
The press release is provided as Exhibit 99.1 and is treated as "furnished" rather than "filed" under securities law, which limits certain legal liabilities and incorporation by reference into other SEC documents unless specifically cited.
BioCardia (BCDA) reported an operational milestone: it announced the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial for patients with “ischemia heart failure of reduced ejection fraction.”
The announcement was made via a press release furnished as Exhibit 99.1. The information is being furnished under Item 8.01 and is not deemed filed under the Exchange Act.
BioCardia (BCDA) scheduled its 2025 annual meeting for 9:00 a.m. PT on December 2, 2025 at Wilson Sonsini in Palo Alto. Stockholders of record as of October 8, 2025 may vote; there were 10,612,734 shares outstanding on the record date.
Stockholders will vote on: (1) the election of three Class III directors; (2) an amended and restated 2016 Equity Incentive Plan to extend the plan to October 31, 2035, change the “evergreen” to 4.0% of outstanding shares added on the meeting date and each fiscal year start, and limit incentive stock option capacity; and (3) ratification of PKF San Diego, LLP as auditor for 2025. The filing also includes a non-binding advisory vote on executive compensation.
Based on shares outstanding on the record date, the initial increase upon approval would be 424,509 shares. As of November 3, 2025, approximately 95,000 shares remained available under the current plan. Audit fees to PKF were $278,000 in 2024 and $261,000 in 2023. Internet/telephone voting closes at 11:59 p.m. ET on December 1, 2025.